AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a significant update for the oncology sector, AstraZeneca, in collaboration with Daiichi Sankyo, is conducting a Phase 3b study titled ‘DESTINY-Breast15’. This study aims to evaluate the safety and efficacy of Trastuzumab Deruxtecan (T-DXd) in patients with hormone receptor-negative and hormone receptor-positive HER2-low or HER2 IHC 0 metastatic breast cancer. The primary goal is to determine the time to next treatment (TTNT), providing insights into the clinical benefits of T-DXd for these patients.
The intervention being tested is Trastuzumab Deruxtecan, an anti-HER2-antibody drug conjugate administered intravenously. It is designed to treat patients with unresectable and/or metastatic breast cancer, focusing on those with HER2-low or HER2 IHC 0 status.
This interventional study is non-randomized with a parallel assignment model and no masking, primarily aimed at treatment. It involves four experimental cohorts based on hormone receptor status and HER2 expression levels.
The study began on December 30, 2023, with the latest update submitted on July 28, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.
The market implications of this study are significant for AstraZeneca and Daiichi Sankyo, as positive results could enhance their stock performance and investor confidence. The study’s outcomes could also influence the competitive landscape in the oncology market, particularly in treatments targeting HER2-low breast cancer.
The study is ongoing, with further details available on the ClinicalTrials portal.